2014 KLCSG-NCC Korea practice guidelines for the management of Hepatocellular carcinoma: HCC diagnostic algorithm

Digestive Diseases

Volumn 32, Issue 6, 2014, Pages 764-777

  Lee, Jeong Min ^a,b   Park, Joong Won ^c   Choi, Byung Ihn ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Clinical Practice Guidelines for HCC; Korea; Korean Liver Cancer Study Group; National Cancer Center

Indexed keywords

COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS; CONTRAST ENHANCEMENT; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; FEMALE; LIVER NEOPLASMS; MALE; NEEDLE BIOPSY; SOUTH KOREA; STANDARDS; STATISTICS AND NUMERICAL DATA;

BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; FEMALE; GUIDELINE ADHERENCE; HUMANS; LIVER NEOPLASMS; MALE; PRACTICE GUIDELINES AS TOPIC; REPUBLIC OF KOREA;

EID: 84910597977     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000368020     Document Type: Conference Paper

References (145)

1. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14.
4. Kudo M: Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 2011;81(suppl 1):73-85.
5. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK: Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33:437-447.
6. Kudo M: Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009;44(suppl 19):112-118.
7. Matsui O, Kobayashi S, Sanada J, Kouda W, Ryu Y, Kozaka K, Kitao A, Nakamura K, Gabata T: Hepatocellular nodules in liver cirrhosis: hemodynamic evaluation (angiographyassisted CT) with special reference to multistep hepatocarcinogenesis. Abdom Imaging 2011;36:264-272.
8. Lee JM, Trevisani F, Vilgrain V, Wald C: Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17(suppl 2):S34-S43.
9. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, Brú C, Bruix J; Barcelona Clinic Liver Cancer Group: MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003;38:1034-1042.
10. Krinsky GA, Lee VS, Theise ND, Weinreb JC, Rofsky NM, Diflo T, Teperman LW: Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219:445-454.
11. Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Chon SB, Lee JM: Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 2006;186:149-157.
12. Lee JM, Yoon JH, Joo I, Woo HS: Recent advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer 2012;1:22-40.
13. Kudo M: Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer 2013;2:69-72.
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
15. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
16. Mitchell DG, Bruix J, Sherman M, Sirlin CB: LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, consensus of the LI-RADS Management Working Group and future directions. Hepatology 2014, Epub ahead of print.
17. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J: New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013;266:376-382.
18. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474.
19. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
20. Korean Liver Cancer Study Group and National Cancer Center, Korea: Practice guidelines for management of hepatocellular carcinoma 2009 (in Korean). Korean J Hepatol 2009;15:391-423.
21. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix J: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
22. Lin MT, Chang KC, Tseng PL, Yen YH, Wang CC, Tsai MC, Cheng YF, Eng HL, Wu CK, Hu TH: The validation of 2010 AASLD guideline for the diagnosis of hepatocellular carcinoma in an endemic area. J Gastroenterol Hepatol 2014, Epub ahead of print.
23. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M: Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan. Ann Surg 2007;245:909-922.
24. Tang A, Cruite I, Sirlin CB: Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol 2013;7:269-279.
25. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
26. Song Do S, Bae SH: Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol 2012;18:258-267.
27. Park JW; Korean Liver Cancer Study Group and National Cancer Center: Practice guideline for diagnosis and treatment of hepatocellular carcinoma (in Korean). Korean J Hepatol 2004;10:88-98.
28. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY: Added value of gadoxetic acidenhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010;255:459-466.
29. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, Choi BI: Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker. Radiology 2013;267:776-786.
30. Choi JY, Lee JM, Sirlin CB: CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50.
31. Sugimoto K, Moriyasu F, Saito K, Taira J, Saguchi T, Yoshimura N, Oshiro H, Imai Y, Shiraishi J: Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med 2012;31:529-538.
32. Hatfield MK, Beres RA, Sane SS, Zaleski GX: Percutaneous imaging-guided solid organ core needle biopsy: coaxial versus noncoaxial method. AJR Am J Roentgenol 2008;190:413-417.
33. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA: Meta-analysis: surveillance with ultrasound for earlystage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
34. Andersson KL, Salomon JA, Goldie SJ, Chung RT: Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418-1424.
35. Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422.
36. Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW: On-treatment alphafetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014;59:986-995.
37. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D: Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 2007;17:2519-2530.
38. Coleman WB: Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3:573-588.
39. Effendi K, Sakamoto M: Molecular pathology in early hepatocarcinogenesis. Oncology 2010;78:157-160.
40. Efremidis SC, Hytiroglou P: The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002;12:753-764.
41. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, Kobayashi S, Gabata T, Zen Y, Yamashita T: The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21:2056-2066.
42. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y: Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography - radiologic-pathologic correlation. Radiology 2009;252:605-614.
43. Park YN, Kim MJ: Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging 2011;36:232-243.
44. Lee JM, Zech CJ, Bolondi L, Jonas E, Kim MJ, Matsui O, Merkle EM, Sakamoto M, Choi BI: Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol 2011;12:403-415.
45. Ito K, Honjo K, Fujita T, Awaya H, Matsumoto T, Matsunaga N, Higuchi M, Kada T, Mattrey RF: Liver neoplasms: diagnostic pitfalls in cross-sectional imaging. Radiographics 1996;16:273-293.
46. Kang Y, Lee JM, Kim SH, Han JK, Choi BI: Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 2012;264:751-760.
47. Kim SA, Lee JM, Lee KB, Kim SH, Yoon SH, Han JK, Choi BI: Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern - correlation with clinicopathologic findings. Radiology 2011;260:148-157.
48. Kim SJ, Lee JM, Han JK, Kim KH, Lee JY, Choi BI: Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol 2007;189:1428-1434.
49. Rimola J, Forner A, Reig M, Vilana R, De Lope CR, Ayuso C, Bruix J: Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009;50:791-798.
50. De Lope CR, Tremosini S, Forner A, Reig M, Bruix J: Management of HCC. J Hepatol 2012;56(suppl 1):S75-S87.
51. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J: Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262-278.
52. Ricke J, Seidensticker M, Mohnike K: Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging. Liver Cancer 2012;1:51-58.
53. Bota S, Piscaglia F, Marinelli S, Pecorelli A, Terzi E, Bolondi L: Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer 2012;1:190-200.
54. Francis IR, Cohan RH, McNulty NJ, Platt JF, Korobkin M, Gebremariam A, Ragupathi KI: Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. AJR Am J Roentgenol 2003;180:1217-1224.
55. Zhao H, Yao JL, Wang Y, Zhou KR: Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J Gastroenterol 2007;13:1252-1256.
56. Huang JS, Pan HB, Chou CP, Liang HL, Yeh LR, Yang TL, Liu SI: Optimizing scanning phases in detecting small (<2 cm) hepatocellular carcinoma: whole-liver dynamic study with multidetector row CT. J Comput Assist Tomogr 2008;32:341-346.
57. Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G, Henry L, Berger F, Bizollon T, Gaudin JL, Ducerf C: Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001;25:327-336.
58. Yu MH, Lee JM, Yoon JH, Baek JH, Han JK, Choi BI, Flohr TG: Low tube voltage intermediate tube current liver MDCT: sinogram-affirmed iterative reconstruction algorithm for detection of hypervascular hepatocellular carcinoma. AJR Am J Roentgenol 2013;201:23-32.
59. Hur S, Lee JM, Kim SJ, Park JH, Han JK, Choi BI: 80-kVp CT using Iterative Reconstruction in Image Space algorithm for the detection of hypervascular hepatocellular carcinoma: phantom and initial clinical experience. Korean J Radiol 2012;13:152-64.
60. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, Della Corte C, Ronchi G, Rumi MG, Biondetti P, Colombo M: The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-644.
61. Lim JH, Kim CK, Lee WJ, Park CK, Koh KC, Paik SW, Joh JW: Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol 2000;175:693-698.
62. Krinsky GA, Lee VS, Theise ND, Weinreb JC, Morgan GR, Diflo T, John D, Teperman LW, Goldenberg AS: Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl 2002;8:1156-1164.
63. Zacherl J, Pokieser P, Wrba F, Scheuba C, Prokesch R, Zacherl M, Langle F, Berlakovich GA, Muhlbacher F, Steininger R: Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Annals Surg 2002;235:528-532.
64. Kim SH, Choi BI, Lee JY, Kim SJ, So YH, Eun HW, Lee JM, Han JK: Diagnostic accuracy of multi-/single-detector row CT and contrastenhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology 2008;51(suppl 1):52-60.
65. Lee JM, Yoon JH, Kim KW: Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012;39:399-409.
66. Mita K, Kim SR, Kudo M, Imoto S, Nakajima T, Ando K, Fukuda K, Matsuoka T, Maekawa Y, Hayashi Y: Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2010;16:4187-4192.
67. Salvaggio G, Campisi A, Lo Greco V, Cannella I, Meloni MF, Caruso G: Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT. Abdom Imaging 2010;35:447-453.
68. Donadon M, Torzilli G: Intraoperative ultrasound in patients with hepatocellular carcinoma: from daily practice to future trends. Liver Cancer 2013;2:16-24.
69. Joo I, Choi BI: New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer 2012;1:94-109.
70. Jang HJ, Kim TK, Wilson SR: Imaging of malignant liver masses: characterization and detection. Ultrasound Q 2006;22:19-29.
71. Kim AY, Lee MW, Rhim H, Cha DI, Choi D, Kim YS, Lim HK, Cho SW: Pretreatment evaluation with contrast-enhanced ultrasonography for percutaneous radiofrequency ablation of hepatocellular carcinomas with poor conspicuity on conventional ultrasonography. Korean J Radiol 2013;14:754-763.
72. Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH: A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912-1921.
73. Granito A, Galassi M, Piscaglia F, Romanini L, Lucidi V, Renzulli M, Borghi A, Grazioli L, Golfieri R, Bolondi L: Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013;37:355-363.
74. Haradome H, Grazioli L, Tinti R, Morone M, Motosugi U, Sano K, Ichikawa T, Kwee TC, Colagrande S: Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011;34:69-78.
75. Holzapfel K, Eiber MJ, Fingerle AA, Bruegel M, Rummeny EJ, Gaa J: Detection, classification, and characterization of focal liver lesions: value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods. Abdom Imaging 2012;37:74-82.
76. Iannicelli E, Di Pietropaolo M, Marignani M, Briani C, Federici GF, Delle Fave G, David V: Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. Radiol Med 2014;119:367-376.
77. Kim JE, Kim SH, Lee SJ, Rhim H: Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol 2011;196:W758-W765.
78. Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, Lee WJ, Lim HK: Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009;192:1675-1681.
79. Kim YK, Lee MW, Lee WJ, Kim SH, Rhim H, Lim JH, Choi D, Kim YS, Jang KM, Lee SJ, Lim HK: Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acidenhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (≤ 1.5 cm in diameter). Invest Radiol 2012;47:159-166.
80. Park MJ, Kim YK, Lee MH, Lee JH: Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol 2013;54:127-136.
81. Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, Han JK, Choi BI: Gadoxetic acidenhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010;45:96-103.
82. Park G, Kim YK, Kim CS, Yu HC, Hwang SB: Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 2010;83:1010-1016.
83. Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, Choi D, Rhim H: Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012;264:761-770.
84. Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, Kudo M, Mochizuki T: Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 2013;266:480-490.
85. Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D: Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 2012;265:104-114.
86. Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kozaka K, Kitao A: Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 2012;81:3002-3009.
87. Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, Ishikawa T: Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011;197:58-63.
88. Takayama Y, Nishie A, Nakayama T, Asayama Y, Ishigami K, Kakihara D, Ushijima Y, Fujita N, Hirakawa M, Honda H: Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. Eur J Radiol 2012;81:3072-3078.
89. Murakami T, Tsurusaki M: Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer 2014;3:85-96.
90. Ichikawa T, Sano K, Morisaka H: Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer 2014;3:97-107.
91. Kudo M: Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 2010;78(suppl 1):87-93.
92. Lee JM, Choi BI: Hepatocellular nodules in liver cirrhosis: MR evaluation. Abdom Imaging 2011;36:282-289.
93. Cruite I, Schroeder M, Merkle EM, Sirlin CB: Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010;195:29-41.
94. Hwang SH, Yu JS, Kim KW, Kim JH, Chung JJ: Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J Comput Assist Tomogr 2008;32:39-45.
95. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667.
96. Kim TK, Lee KH, Jang HJ, Haider MA, Jacks LM, Menezes RJ, Park SH, Yazdi L, Sherman M, Khalili K: Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2 cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011;259:730-738.
97. Rimola J, Forner A, Tremosini S, Reig M, Vilana R, Bianchi L, Rodriguez-Lope C, Sole M, Ayuso C, Bruix J: Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 2012;56:1317-1323.
98. Khan AS, Hussain HK, Johnson TD, Weadock WJ, Pelletier SJ, Marrero JA: Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 2010;32:360-366.
99. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS: Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281-289.
100. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, Bolondi L: The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010;105:599-609.
101. Arif-Tiwari H, Kalb B, Chundru S, Sharma P, Costello J, Guessner RW, Martin DR: MRI of hepatocellular carcinoma: an update of current practices. Diagn Interv Radiol 2014;20:209-221.
102. Davenport MS, Khalatbari S, Liu PS, Maturen KE, Kaza RK, Wasnik AP, Al-Hawary MM, Glazer DI, Stein EB, Patel J, Somashekar DK, Viglianti BL, Hussain HK: Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 2014;272:132-142.
103. Jha RC, Mitchell DG, Weinreb JC, Santillan CS, Yeh BM, Francois R, Sirlin CB: LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas. AJR Am J Roentgenol 2014;203:W48-W69.
104. Purysko AS, Remer EM, Coppa CP, Leao Filho HM, Thupili CR, Veniero JC: LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics 2012;32:1977-1995.
105. Jang KM, Kim SH, Kim YK, Choi D: Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Acta Radiol 2014, Epub ahead of print.
106. Kim HS, Choi D, Kim SH, Lee MW, Lee WJ, Kim YK, Jang KM, Park MJ, Park CK: Changes in the signal- and contrast-to-noise ratios of hepatocellular carcinomas on gadoxetic acid-enhanced dynamic MR imaging. Eur J Radiol 2013;82:62-68.
107. Simon G, Link TM, Wortler K, Doebereiner F, Schulte-Frohlinde E, Daldrup-Link H, Settles M, Rummeny EJ: Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol 2005;15:895-903.
108. Akai H, Kiryu S, Matsuda I, Satou J, Takao H, Tajima T, Watanabe Y, Imamura H, Kokudo N, Akahane M, Ohtomo K: Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol 2011;80:310-315.
109. Bashir MR, Gupta RT, Davenport MS, Allen BC, Jaffe TA, Ho LM, Boll DT, Merkle EM: Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging 2013;37:398-406.
110. Kim YK, Kim CS, Han YM, Park G: Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol 2010;45:740-746.
111. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, Taura K, Yasuchika K, Nitta T, Ikai I, Uemoto S: Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44:793-798.
112. Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, Kozaka K, Yoneda N, Yamashita T, Kaneko S, Nakanuma Y: Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging - correlation with molecular transporters and histopathologic features. Radiology 2010;256:817-826.
113. Tanimoto A, Kuwatsuru R, Kadoya M, Ohtomo K, Hirohashi S, Murakami T, Hiramatsu K, Yoshikawa K, Katayama H: Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: results from phase II and phase III clinical trials in Japan. J Magn Reson Imaging 1999;10:450-460.
114. Marin D, Di Martino M, Guerrisi A, De Filippis G, Rossi M, Ginanni Corradini S, Masciangelo R, Catalano C, Passariello R: Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009;251:85-95.
115. Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, Kudo M: Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors. Dig Dis 2013;31:472-479.
116. Motosugi U: Hypovascular hypointense nodules on hepatocyte phase gadoxetic acidenhanced MR images: too early or too progressed to determine hypervascularity. Radiology 2013;267:317-318.
117. Chou CT, Chen YL, Su WW, Wu HK, Chen RC: Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocytephase imaging. J Magn Reson Imaging 2010;32:895-902.
118. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L: Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011;21:1233-1242.
119. Chen WX, Min PQ, Song B, Xiao BL, Liu Y, Ge YH: Single-level dynamic spiral CT of hepatocellular carcinoma: correlation between imaging features and density of tumor microvessels. World J Gastroenterol 2004;10:67-72.
120. Grazioli L, Olivetti L, Fugazzola C, Benetti A, Stanga C, Dettori E, Gallo C, Matricardi L, Giacobbe A, Chiesa A: The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol 1999;9:62-67.
121. Ishigami K, Yoshimitsu K, Nishihara Y, Irie H, Asayama Y, Tajima T, Nishie A, Hirakawa M, Ushijima Y, Okamoto D, Taketomi A, Honda H: Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009;250:435-443.
122. Lee MH, Kim SH, Park MJ, Park CK, Rhim H: Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusionweighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol 2011;197:W868-W875.
123. Nakamura Y, Toyota N, Date S, Oda S, Namimoto T, Yamashita Y, Beppu T, Awai K: Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results. J Comput Assist Tomogr 2011;35:723-727.
124. Chong YS, Kim YK, Lee MW, Kim SH, Lee WJ, Rhim HC, Lee SJ: Differentiating massforming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 2012;67:766-773.
125. Park HJ, Kim YK, Park MJ, Lee WJ: Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 2013;38:793-801.
126. Pradella S, Lucarini S, Colagrande S: Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma. AJR Am J Roentgenol 2012;199:W662.
127. Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L: Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 2009;19(suppl 5):S975-S989.
128. Bruegel M, Holzapfel K, Gaa J, Woertler K, Waldt S, Kiefer B, Stemmer A, Ganter C, Rummeny EJ: Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted singleshot echo-planar MR imaging technique. Eur Radiol 2008;18:477-485.
129. Haradome H, Grazioli L, Morone M, Gambarini S, Kwee TC, Takahara T, Colagrande S: T2-weighted and diffusion-weighted MRI for discriminating benign from malignant focal liver lesions: diagnostic abilities of single versus combined interpretations. J Magn Reson Imaging 2012;35:1388-1396.
130. Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, Kaneoka Y, Maeda A: Nonhypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol 2013;58:1174-1180.
131. Yamamoto A, Ito K, Tamada T, Higaki A, Kanki A, Sato T, Tanimoto D: Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI. AJR Am J Roentgenol 2013;200:1254-1260.
132. Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, Nakano M, Sakamoto M, Nakazawa T, Asakawa M, Fujii H, Kitamura T, Enomoto N, Araki T: Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011;261:834-844.
133. Bartolozzi C, Battaglia V, Bargellini I, Bozzi E, Campani D, Pollina LE, Filipponi F: Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 2013;38:290-296.
134. Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, Mochizuki T: Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol 2012;30:743-751.
135. Matsui O: Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol 2005;3 (10 suppl 2):S136-S140.
136. Piscaglia F, Bolondi L: Recent advances in the diagnosis of hepatocellular carcinoma. Hepatol Res 2007;37(suppl 2):S178-S192.
137. Lee J, Lee WJ, Lim HK, Lim JH, Choi N, Park MH, Kim SW, Park CK: Early hepatocellular carcinoma: three-phase helical CT features of 16 patients. Korean J Radiol 2008;9:325-332.
138. Lee JH, Lee JM, Kim SJ, Baek JH, Yun SH, Kim KW, Han JK, Choi BI: Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. Br J Radiol 2012;85:e573-e583.
139. Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, Han JK, Choi BI: Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 2009;193:W482-W489.
140. Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, Choi BI: Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 2014;271:748-760.
141. Golfieri R, Marini E, Bazzocchi A, Fusco F, Trevisani F, Sama C, Mazzella G, Cavuto S, Piscaglia F, Bolondi L: Small (< or = 3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging versus multidetector-row CT. Radiol Med 2009;114:1239-1266.
142. Bae SY, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC: Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area. Clin Mol Hepatol 2012;18:185-194.
143. Moon JI, Kwon CH, Joh JW, Choi GS, Jung GO, Kim JM, Shin M, Choi SJ, Kim SJ, Lee SK: Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival. Transplant Proc 2012;44:487-493.
144. Kojiro M: Pathological diagnosis at early stage: reaching international consensus. Oncology 2010;78(suppl 1):31-35.
145. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF: Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57:1592-1596.